¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ½ÃÀå : »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå µ¿Çâ, ¿¹Ãø(2025-2032³â)
Biomarker Discovery Outsourcing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â ¼¼°è ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ º¸°í¼¸¦ ¹ßÇ¥ÇÏ¿© ÃßÁø·Â, »õ·Î¿î µ¿Çâ, ±âȸ, °úÁ¦ µî ÁÖ¿ä ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®À» Á¦°øÇß½À´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå ±Ô¸ð(2025³â) : 148¾ï ´Þ·¯
½ÃÀå ±Ô¸ð ¿¹Ãø(±Ý¾× ±âÁØ, 2032³â) : 384¾ï ´Þ·¯
¼¼°è ½ÃÀåÀÇ ¼ºÀå·ü(CAGR, 2025-2032³â) : 14.5%
¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå ºÐ¼® ¹üÀ§
¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀåÀº ÀǾàǰ °³¹ß ¹× Áúº´ Áø´Ü¿¡ »ç¿ëµÇ´Â »ý¹°ÇÐÀû ¸¶Ä¿¸¦ È®ÀÎÇÏ°í °ËÁõÇϱâ À§ÇÑ Àü¹® ¼ºñ½ºÀÇ ¾Æ¿ô¼Ò½ÌÀ» ¸»ÇÕ´Ï´Ù. ¾àǰ °³¹ßÀÇ º¹À⼺ÀÌ ´Ã¾î³²¿¡ µû¶ó ±â¾÷Àº ÷´Ü ±â¼ú°ú Àü¹® Áö½ÄÀ» ÀÌ¿ëÇÏ°í ºñ¿ëÀ» Àý°¨Çϰí ÀÏÁ¤À» ´ÜÃàÇϱâ À§ÇØ °³¹ß ¾÷¹« ¼öʱâ°ü(CRO)°ú ¿ÜºÎ ¼ºñ½º Á¦°ø¾÷ü¸¦ ÀÌ¿ëÇÏ°Ô µÇ¾î ¿Ô½À´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀº ¿©·¯ °¡Áö°¡ ÀÖ½À´Ï´Ù. ¾Ï, ½ÉÇ÷°ü Áúȯ, ½Å°æ Áúȯ µîÀÇ ¸¸¼º ÁúȯÀ̳ª º¹ÀâÇÑ ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö¿¡ Å©°Ô ÀÇÁ¸ÇÏ´Â Á¤¹ÐÀÇ·áÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ ±â¼ú Áøº¸¿¡ ÀÇÇØ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ÀÇ µ¿Á¤ÀÌ ¿ëÀÌÇÏ°Ô µÇ¾î, ½ÃÀå ¼ö¿ä°¡ ÇÑÃþ ´õ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :
°ß°íÇÑ ¼ºÀåÀÌ ¿¹»óµÇ´Â ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀåÀº ¿©·¯ °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ º¸¾È ¹®Á¦¿Í ÁöÀû Àç»ê±Ç(IP) À§Çèµµ ƯÈ÷ ±¹°æ °£ Çù¾÷¿¡¼ »ó´çÇÑ À庮À» Á¦±âÇÕ´Ï´Ù. ¶ÇÇÑ, ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·°ú ¹ÙÀÌ¿À¸¶Ä¿ Á¶»ç ±â¹ýÀÇ Ç¥ÁØÈÀÇ ÇѰè´Â ¼ºñ½ºÀÇ Áú°ú ÀçÇö¼º¿¡ ¿µÇâÀ» ¹ÌÄ¡°í, ÀÓ»ó °á°ú¿¡ ¿µÇâÀ» ¹ÌÄ¥ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ :
¸ÂÃãÇü Ä¡·á¿Í Á¤¹Ð Áø´Ü ¼ö¿ä°¡ ¼¼°èÀûÀ¸·Î ³ô¾ÆÁö´Â °¡¿îµ¥, ÀÌ ½ÃÀå¿¡´Â Å« ºñÁî´Ï½º ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. ¾Æ½Ã¾Æ ÅÂÆò¾ç ¹× ¶óƾ ¾Æ¸Þ¸®Ä«ÀÇ ½ÅÈï ½ÃÀåÀº Áõ°¡Çϴ ȯÀÚ ±â¹Ý, Áõ°¡ÇÏ´Â ÀÇ·á ÀÎÇÁ¶ó, ºñ¿ë ÀÌÁ¡À¸·Î ÀÎÇØ ¹Ì°³Ã´ ÀáÀç·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®¿¡ ÀÖ¾î¼ÀÇ ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×(ML)ÀÇ ÅëÇÕÀº Ž»öÀÇ ½ºÇǵå¿Í Á¤¹Ðµµ¸¦ ³ôÀ̰í, Çõ½ÅÀÇ »õ·Î¿î ±æÀ» ¿±´Ï´Ù. CRO¿Í Á¦¾à ±â¾÷ÀÇ Àü·«Àû Á¦ÈÞ, ÇÕº´, Àμö´Â ´É·Â°ú ¼ºñ½º Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´äº¯À» ¾òÀ» ¼ö ÀÖ´Â ÁÖ¿ä Áú¹®
¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº? ¾Æ¿ô¼Ò½Ì ¼ºñ½º ¼ö¿ä°¡ °¡Àå ³ôÀº Ä¡·á ºÐ¾ß¿Í Ž»ö ´Ü°è´Â? À¯ÀüüÇÐ¿Í AIÀÇ ±â¼úÁøº¸´Â ½ÃÀå ¿ªÇп¡ ¾î¶² ¿µÇâÀ» ÁÖ°í Àִ°¡? ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ¾î´À °ÍÀ¸·Î, ¾î¶² Àü·«À» ä¿ëÇϰí Àִ°¡? ¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ°ú ¿¹ÃøÀº?
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¾ïÁ¦¿äÀÎ
±âȸ
°úÁ¦
ÁÖ¿ä µ¿Çâ
°Å½Ã°æÁ¦ ¿äÀÎ
±¹Á¦¹«¿ªÁ¤Ã¥ÀÌ ºÐ¼®±â±â¿¡ ¹ÌÄ¡´Â ¿µÇâ
°æÁ¦È¸º¹°ú ÀǷῬ±¸ºñ Áõ°¡
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø ¿äÀÎ : °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ºÐ¼®
¹ÙÀÌ¿À¸¶Ä¿ À¯Çü ¼ö¿ä ºÐ¼®
±ÔÁ¦ »óȲ
¹ë·ùüÀÎ ºÐ¼®
PESTLE ºÐ¼®
Porter's Five Forces ºÐ¼®
Á¦4Àå ¼¼°è ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð ¿¹Ãø(¼ö·® ±âÁØ)
½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü(±Ý¾× ±âÁØ(10¾ï ´Þ·¯))
Àý´ë ¼öÀÍ ±âȸ
½ÃÀå ±Ô¸ðÀÇ ºÐ¼®°ú ¿¹Ãø(±Ý¾× ±âÁØ(10¾ï ´Þ·¯))
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®(±Ý¾× ±âÁØ(10¾ï ´Þ·¯), 2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ðÀÇ ºÐ¼®°ú ¿¹Ãø(±Ý¾× ±âÁØ(10¾ï ´Þ·¯), 2025-2032³â)
¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á : ¹ÙÀÌ¿À¸¶Ä¿À¯Çüº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : À¯Çüº°(±Ý¾×(10¾ï ´Þ·¯) ¹× ¼ö·® ±âÁØ, 2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ðÀÇ ºÐ¼®°ú ¿¹Ãø : À¯Çüº°(±Ý¾×(10¾ï ´Þ·¯) ¹× ¼ö·® ±âÁØ, 2025-2032³â)
¿¹Ãø ¹ÙÀÌ¿À¸¶Ä¿
¿¹ÈÄ ¹ÙÀÌ¿À¸¶Ä¿
¾ÈÀü¼º ¹ÙÀÌ¿À¸¶Ä¿
´ëü ¹ÙÀÌ¿À¸¶Ä¿
½ÃÀå ¸Å·Â ºÐ¼® : ¹ÙÀÌ¿À ¸¶Ä¿À¯Çüº°
¼¼°è ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á : Ä¡·á¿µ¿ªº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : À¯Çüº°(±Ý¾× ±âÁØ(10¾ï ´Þ·¯), 2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ðÀÇ ºÐ¼®°ú ¿¹Ãø : À¯Çüº°(±Ý¾× ±âÁØ(10¾ï ´Þ·¯), 2025-2032³â)
Á¾¾ç
½ÉÀ庴
½Å°æÁõ
ÀÚ°¡¸é¿ªÁúȯ
±âŸ
½ÃÀå ¸Å·Â ºÐ¼® : Ä¡·á ¿µ¿ªº°
¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á : Ž»ö ´Ü°èº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Ž»ö ´Ü°èº°(±Ý¾× ±âÁØ(10¾ï ´Þ·¯), 2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ðÀÇ ºÐ¼®°ú ¿¹Ãø : Ž»ö ´Ü°èº°(±Ý¾× ±âÁØ(10¾ï ´Þ·¯), 2025-2032³â)
¹ÙÀÌ¿À¸¶Ä¿ÀÇ µ¿Á¤
¹ÙÀÌ¿À¸¶Ä¿ÀÇ °ËÁõ
¹ÙÀÌ¿À¸¶Ä¿ÇÁ·ÎÆÄÀϸµ
¹ÙÀÌ¿À¸¶Ä¿ ÆÐ³Î °³¹ß
¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¼±ÅÃ
½ÃÀå ¸Å·Â ºÐ¼® : Ž»ö ´Ü°èº°
¼¼°è ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á : ÃÖÁ¾ ¿ëµµº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ÃÖÁ¾ ¿ëµµº°(±Ý¾× ±âÁØ(10¾ï ´Þ·¯), 2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ðÀÇ ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°(±Ý¾× ±âÁØ(10¾ï ´Þ·¯), 2025-2032³â)
Á¦¾àȸ»ç
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
±âŸ
½ÃÀå ¸Å·Â ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á : Áö¿ªº°
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Áö¿ªº°(±Ý¾×(10¾ï ´Þ·¯)¡¤¼ö·® ±âÁØ, 2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ðÀÇ ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°(±Ý¾×(10¾ï ´Þ·¯)¡¤¼ö·® ±âÁØ, 2025-2032³â)
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ªº°
Á¦6Àå ºÏ¹Ì ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á
Á¦7Àå À¯·´ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á
Á¦8Àå µ¿¾Æ½Ã¾Æ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á
Á¦9Àå ³²¾Æ½Ã¾Æ ¿À¼¼¾Æ´Ï¾ÆÀÇ ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¾Æ¿ô¼Ò½Ì ¼ºñ½º ½ÃÀå Àü¸Á
Á¦12Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®(2025³â)
½ÃÀå ±¸Á¶
°æÀï °µµ ¸Ê : ½ÃÀ庰
°æÀï ´ë½Ãº¸µå
±â¾÷ ÇÁ·ÎÆÄÀÏ(»ó¼¼: °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
Laboratory Corporation of America Holdings
Celerion
Charles River Laboratories
Eurofins Scientific
GHO Capital
ICON plc
Evotec
Parexel International(MA) Corporation
Thermo Fisher Scientific Inc.
Proteome Sciences
Others
Á¦13Àå ºÎ·Ï
ºÐ¼® ¹æ¹ý
ºÐ¼®ÀÇ ÀüÁ¦Á¶°Ç
µÎÀÚ¾î ¹× ¾à¾î
SHW
Persistence Market Research has recently released a comprehensive report on the global Biomarker Discovery Outsourcing Services Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.
Key Insights:
Biomarker Discovery Outsourcing Services Market Size (2025E): US$ 14.8 Bn
Projected Market Value (2032F): US$ 38.4 Bn
Global Market Growth Rate (CAGR 2025 to 2032): 14.5%
Biomarker Discovery Outsourcing Services Market - Report Scope:
The biomarker discovery outsourcing services market refers to the outsourcing of specialized services to identify and validate biological markers used in drug development and disease diagnosis. This includes services related to biomarker identification, validation, profiling, and selection, often utilized by pharmaceutical and biotechnology companies. As the complexity of drug development increases, companies are increasingly turning to contract research organizations (CROs) and external service providers to access advanced technologies and expertise, reduce costs, and accelerate timelines. The rising demand for personalized medicine, the surge in chronic diseases, and the need for efficient clinical trials are accelerating the growth of this market.
Market Growth Drivers:
The market is witnessing significant growth due to several key drivers. The increasing prevalence of chronic and complex diseases such as cancer, cardiovascular, and neurological disorders has heightened the need for precision medicine, which relies heavily on biomarker discovery. Pharmaceutical and biotechnology companies are under pressure to enhance drug development efficiency, pushing them to outsource complex biomarker research to reduce time and cost. Technological advancements in genomics, proteomics, and bioinformatics have made it easier to identify novel biomarkers, further stimulating market demand. Additionally, the regulatory support for biomarker-based clinical trials and drug approvals is encouraging investment in outsourced biomarker discovery services.
Market Restraints:
Despite robust growth prospects, the biomarker discovery outsourcing services market faces several challenges. High service costs and the complexity of biomarker validation processes can deter small and mid-sized enterprises from outsourcing. Data security concerns and intellectual property (IP) risks also pose significant barriers, especially in cross-border collaborations. Moreover, a shortage of skilled professionals and limited standardization in biomarker research methodologies can impact service quality and reproducibility, potentially affecting clinical outcomes. Variability in regulatory frameworks across regions may further hinder seamless outsourcing operations and market expansion.
Market Opportunities:
The market presents significant opportunities as demand for personalized therapies and precision diagnostics grows globally. Increasing R&D investments by pharmaceutical and biotech firms in developing targeted therapies are expected to boost outsourcing needs. Emerging markets in Asia-Pacific and Latin America offer untapped potential due to a rising patient base, growing healthcare infrastructure, and cost advantages. The integration of artificial intelligence (AI) and machine learning (ML) in biomarker analysis opens new avenues for innovation, enhancing discovery speed and accuracy. Strategic partnerships, mergers, and acquisitions among CROs and pharmaceutical companies can further accelerate market growth by expanding capabilities and service portfolios.
Key Questions Answered in the Report:
What are the primary factors driving the global biomarker discovery outsourcing services market's growth?
Which therapeutic areas and discovery phases are seeing the highest demand for outsourced services?
How are technological advancements in genomics and AI influencing market dynamics?
Who are the key players in the biomarker discovery outsourcing services market, and what strategies are they adopting?
What are the emerging trends and future projections for the global biomarker discovery outsourcing services market?
Competitive Intelligence and Business Strategy:
Leading companies in the global biomarker discovery outsourcing services market, such as Laboratory Corporation of America Holdings, Celerion, Charles River Laboratories, and Thermo Fisher Scientific Inc., are focusing on expanding their biomarker service offerings and enhancing technological capabilities. Strategic collaborations with pharmaceutical firms and acquisitions of niche CROs are common strategies to gain a competitive edge. These companies are also investing in AI-powered analytics platforms and multi-omics approaches to improve biomarker identification and validation. By strengthening global laboratory networks and ensuring compliance with evolving regulatory standards, these players aim to meet growing industry demands efficiently.
Companies Covered in This Report:
Laboratory Corporation of America Holdings
Celerion
Charles River Laboratories
Eurofins Scientific
GHO Capital
ICON plc
Evotec
Parexel International (MA) Corporation
Thermo Fisher Scientific Inc.
Proteome Sciences
Market Segmentation:
By Biomarker Type:
Predictive Biomarkers
Prognostic Biomarkers
Safety Biomarkers
Surrogate Biomarkers
By Therapeutic Area:
Oncology
Cardiology
Neurology
Autoimmune Diseases
Others
By Discovery Phase:
Biomarker Identification
Biomarker Validation
Biomarker Profiling
Biomarker Panel Development
Biomarker Selection
By End-use:
Pharmaceutical Companies
Biotechnology Companies
Others
By Region:
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Table of Contents
1. Executive Summary
1.1. Global Biomarker Discovery Outsourcing Services Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Key Trends
2.3. Macro-economic Factors
2.3.1. Impact of International Trade Policies on Analytical Instruments
2.3.2. Economic Recovery and Increased Research Spending in Healthcare
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Biomarker Type Demand Analysis
3.2. Regulatory Landscape
3.3. Value Chain Analysis
3.4. PESTLE Analysis
3.5. Porter's Five Force Analysis
4. Global Biomarker Discovery Outsourcing Services Market Outlook
4.1. Key Highlights
4.1.1. Market Volume (Units) Projections
4.1.2. Market Size (US$ Bn) and Y-o-Y Growth
4.1.3. Absolute $ Opportunity
4.2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
4.3. Global Biomarker Discovery Outsourcing Services Market Outlook: Biomarker Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Biomarker Type, 2019-2024
4.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
4.3.3.1. Predictive Biomarkers
4.3.3.2. Prognostic Biomarkers
4.3.3.3. Safety Biomarkers
4.3.3.4. Surrogate Biomarkers
4.3.4. Market Attractiveness Analysis: Biomarker Type
4.4. Global Biomarker Discovery Outsourcing Services Market Outlook: Therapeutic Area
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Therapeutic Area, 2019-2024
4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
4.4.3.1. Oncology
4.4.3.2. Cardiology
4.4.3.3. Neurology
4.4.3.4. Autoimmune Diseases
4.4.3.5. Others
4.4.4. Market Attractiveness Analysis: Therapeutic Area
4.5. Global Biomarker Discovery Outsourcing Services Market Outlook: Discovery Phase
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Discovery Phase, 2019-2024
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
4.5.3.1. Biomarker Identification
4.5.3.2. Biomarker Validation
4.5.3.3. Biomarker Profiling
4.5.3.4. Biomarker Panel Development
4.5.3.5. Biomarker Selection
4.5.4. Market Attractiveness Analysis: Discovery Phase
4.6. Global Biomarker Discovery Outsourcing Services Market Outlook: End Use
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Bn) Analysis, By End Use, 2019-2024
4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
4.6.3.1. Pharmaceutical Companies
4.6.3.2. Biotechnology Companies
4.6.3.3. Others
4.6.4. Market Attractiveness Analysis: End Use
5. Global Biomarker Discovery Outsourcing Services Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Biomarker Discovery Outsourcing Services Market Outlook
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Biomarker Type
6.2.3. By Therapeutic Area
6.2.4. By Discovery Phase
6.2.5. By End Use
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
6.4.1.
6.4.1.1.
6.4.1.1.1. Predictive Biomarkers
6.4.1.1.2. Prognostic Biomarkers
6.4.1.1.3. Safety Biomarkers
6.4.1.1.4. Surrogate Biomarkers
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
6.5.1. Oncology
6.5.2. Cardiology
6.5.3. Neurology
6.5.4. Autoimmune Diseases
6.5.5. Others
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
6.6.1. Biomarker Identification
6.6.2. Biomarker Validation
6.6.3. Biomarker Profiling
6.6.4. Biomarker Panel Development
6.6.5. Biomarker Selection
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
6.7.1. Pharmaceutical Companies
6.7.2. Biotechnology Companies
6.7.3. Others
6.8. Market Attractiveness Analysis
7. Europe Biomarker Discovery Outsourcing Services Market Outlook
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Biomarker Type
7.2.3. By Therapeutic Area
7.2.4. By Discovery Phase
7.2.5. By End Use
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
7.4.1.
7.4.1.1.
7.4.1.1.1. Predictive Biomarkers
7.4.1.1.2. Prognostic Biomarkers
7.4.1.1.3. Safety Biomarkers
7.4.1.1.4. Surrogate Biomarkers
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
7.5.1. Oncology
7.5.2. Cardiology
7.5.3. Neurology
7.5.4. Autoimmune Diseases
7.5.5. Others
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
7.6.1. Biomarker Identification
7.6.2. Biomarker Validation
7.6.3. Biomarker Profiling
7.6.4. Biomarker Panel Development
7.6.5. Biomarker Selection
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
7.7.1. Pharmaceutical Companies
7.7.2. Biotechnology Companies
7.7.3. Others
7.8. Market Attractiveness Analysis
8. East Asia Biomarker Discovery Outsourcing Services Market Outlook
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Biomarker Type
8.2.3. By Therapeutic Area
8.2.4. By Discovery Phase
8.2.5. By End Use
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
8.4.1.
8.4.1.1.
8.4.1.1.1. Predictive Biomarkers
8.4.1.1.2. Prognostic Biomarkers
8.4.1.1.3. Safety Biomarkers
8.4.1.1.4. Surrogate Biomarkers
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
8.5.1. Oncology
8.5.2. Cardiology
8.5.3. Neurology
8.5.4. Autoimmune Diseases
8.5.5. Others
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
8.6.1. Biomarker Identification
8.6.2. Biomarker Validation
8.6.3. Biomarker Profiling
8.6.4. Biomarker Panel Development
8.6.5. Biomarker Selection
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
8.7.1. Pharmaceutical Companies
8.7.2. Biotechnology Companies
8.7.3. Others
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Biomarker Discovery Outsourcing Services Market Outlook
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Biomarker Type
9.2.3. By Therapeutic Area
9.2.4. By Discovery Phase
9.2.5. By End Use
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
9.4.1.
9.4.1.1.
9.4.1.1.1. Predictive Biomarkers
9.4.1.1.2. Prognostic Biomarkers
9.4.1.1.3. Safety Biomarkers
9.4.1.1.4. Surrogate Biomarkers
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
9.5.1. Oncology
9.5.2. Cardiology
9.5.3. Neurology
9.5.4. Autoimmune Diseases
9.5.5. Others
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
9.6.1. Biomarker Identification
9.6.2. Biomarker Validation
9.6.3. Biomarker Profiling
9.6.4. Biomarker Panel Development
9.6.5. Biomarker Selection
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
9.7.1. Pharmaceutical Companies
9.7.2. Biotechnology Companies
9.7.3. Others
9.8. Market Attractiveness Analysis
10. Latin America Biomarker Discovery Outsourcing Services Market Outlook
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Biomarker Type
10.2.3. By Therapeutic Area
10.2.4. By Discovery Phase
10.2.5. By End Use
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
10.4.1.
10.4.1.1.
10.4.1.1.1. Predictive Biomarkers
10.4.1.1.2. Prognostic Biomarkers
10.4.1.1.3. Safety Biomarkers
10.4.1.1.4. Surrogate Biomarkers
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
10.5.1. Oncology
10.5.2. Cardiology
10.5.3. Neurology
10.5.4. Autoimmune Diseases
10.5.5. Others
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
10.6.1. Biomarker Identification
10.6.2. Biomarker Validation
10.6.3. Biomarker Profiling
10.6.4. Biomarker Panel Development
10.6.5. Biomarker Selection
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
10.7.1. Pharmaceutical Companies
10.7.2. Biotechnology Companies
10.7.3. Others
10.8. Market Attractiveness Analysis
11. Middle East & Africa Biomarker Discovery Outsourcing Services Market Outlook
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Biomarker Type
11.2.3. By Therapeutic Area
11.2.4. By Discovery Phase
11.2.5. By End Use
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
11.4.1.
11.4.1.1.
11.4.1.1.1. Predictive Biomarkers
11.4.1.1.2. Prognostic Biomarkers
11.4.1.1.3. Safety Biomarkers
11.4.1.1.4. Surrogate Biomarkers
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
11.5.1. Oncology
11.5.2. Cardiology
11.5.3. Neurology
11.5.4. Autoimmune Diseases
11.5.5. Others
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
11.6.1. Biomarker Identification
11.6.2. Biomarker Validation
11.6.3. Biomarker Profiling
11.6.4. Biomarker Panel Development
11.6.5. Biomarker Selection
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
11.7.1. Pharmaceutical Companies
11.7.2. Biotechnology Companies
11.7.3. Others
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Laboratory Corporation of America Holdings
12.3.1.1. Overview
12.3.1.2. Segments and Biomarker Types
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Celerion
12.3.3. Charles River Laboratories
12.3.4. Eurofins Scientific
12.3.5. GHO Capital
12.3.6. ICON plc
12.3.7. Evotec
12.3.8. Parexel International (MA) Corporation
12.3.9. Thermo Fisher Scientific Inc.
12.3.10. Proteome Sciences
12.3.11. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations